You are here

Approvable Letter Issued for Abetimus Sodium, Lupus Treatment

SAN DIEGO, Oct. 14 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company (Nasdaq: LJPC - News) announced today that the Company has received a letter from the United States Food and Drug Administration (FDA) indicating that its lupus drug candidate, Riquent® (abetimus sodium), is approvable, but that an additional randomized, double-blind study demonstrating the clinical benefit of Riquent would need to be completed prior to approval. The FDA letter indicated that the ongoing clinical trial initiated in August 2004 would appear to satisfy this requirement.

The Company continues to review the letter and has requested a meeting with the FDA to discuss the next steps in the development of Riquent. Until that meeting is held, the Company will be able to provide only limited guidance.

Source: La Jolla Pharmaceutical Company

Recent Headlines

Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients
Zip Device Faster to Apply, Minimizes Scarring
Statistically Significant Improvement in Excessive Daytime Sleepiness
Researcher Made Himself Guinea Pig to Test the Drug
Treatment Shorter, Less Complicated Than Typical Regimen